TEL AVIV, Israel, December 14 Sigma Pharmaceuticals Ltd.and Neurim Pharmaceuticals Ltd. announce Licensing Agreement for Circadin(R)- prolonged release melatonin for primary insomnia in Australia.

Circadin is approved for longer use in patients with primary insomnia, aged 55 years or over.1 Following an extension to its current licence, doctors can now prescribe Circadin for a period of up to ...

Circadin is indicated for the treatment of primary insomnia in patients who are aged 55 or over. The approval was based primarily on data obtained in the latest SOUNDER-SLEEP Phase IV clinical study, ...

EC approves change in primary insomnia treatment duration with Circadin from 3 to 13 weeks ...

For some, getting a good night's sleep remains elusive. Neurim Pharmaceuticals hopes to change all that with its new drug Circadin. Traditional sleeping pills have many side effects. Now an Israeli ...

COPENHAGEN, Sept 24 (Reuters) - Danish pharmaceutical group Lundbeck said on Monday it licensed the European rights to the insomnia drug Circadin from Neurim Pharmaceuticals Ltd. Israel-based Neurim ...

If you're over 55 and have spent more than a few sleepless nights, you're not alone -- insomnia affects about half of all people over 55 -- but you may also be at increased risk for physical and ...

Lundbeck is celebrating the European launch of Circadin, a new, first-in-class sleep medication which the Danish firm says will offer “hope for thousands of sufferers of insomnia”. Lundbeck is ...

If you're over 55 and have spent more than a few sleepless nights, you're not alone -- insomnia affects about half of all people over 55 -- but you may also be at increased risk for physical and ...

Circadin ® (prolonged release melatonin) licence extended to include treatment for up to 13 weeks¹ in patients with primary insomnia Dialogue with elderly patients Prescribing information The role of ...

Circadin (R), currently approved for use in 33 countries, is a novel sleep aid indicated for treatment of primary insomnia. The latest approval in Australia by the TGA, was based on clinical studies ...